Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benlysta Decision Likely To Be Delayed By Negotiations On Labeling

Executive Summary

The Arthritis Advisory Committee's call for FDA to tailor labeling to restrict claims of efficacy to the clinical trial population for Human Genome Sciences' lupus drug Benlysta (belimumab) will likely push a decision on the drug beyond its Dec. 9 user fee date.
Advertisement

Related Content

Benlysta In GSK’s Hands: A Slow-but-steady Launch, Or A Dud?
HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions
HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions
With PDUFA Date Coming Up, HGSI Optimistically Outlines Launch Plans For Benlysta
With PDUFA Date Coming Up, HGSI Optimistically Outlines Launch Plans For Benlysta
Benlysta May Lead Wave Of New Approvals For Lupus Drugs
Variety of Issues Undermine Efficacy Data As FDA Takes Benlysta To Advisory Panel
Variety of Issues Undermine Efficacy Data As FDA Takes Benlysta To Advisory Panel

Topics

Advertisement
UsernamePublicRestriction

Register

PS052854

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel